Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Immunol Methods. 2012 Sep 28;383(1-2):39-46. doi: 10.1016/j.jim.2012.05.017. Epub 2012 Jun 6.
There remains considerable controversy in the management of eosinophilic disorders, mainly due to a paucity of information regarding the clinical interpretation of total blood eosinophil counts versus surface activation markers versus eosinophil-derived or eosinophil-influencing mediator levels. Regrettably, few tests have been validated that define a unique clinical or prognostic phenotype that is more useful than simply monitoring total blood eosinophil counts. In this manuscript, phenotypic (cell surface) markers, along with serum and tissue-based markers that have been examined in the context of disease activity, are reviewed. We also report the development of a novel assay for detecting soluble Siglec-8 (sSiglec-8), a protein likely derived largely from eosinophils, as a potential serum biomarker. The assay consists of a competitive ELISA using a recombinant Siglec-8-Fc fusion protein. The goal of this preliminary study was to determine if sSiglec-8 is a useful biomarker that differentiates among patients with various eosinophil-associated diseases. In the final analysis, it is fair to say that further research is sorely needed to fully understand and validate the utility of various biomarkers, including sSiglec-8, before their use in clinical practice can be recommended with confidence.
在嗜酸性粒细胞疾病的治疗中仍存在相当大的争议，主要是由于缺乏有关总血嗜酸性粒细胞计数与表面激活标志物与嗜酸性粒细胞衍生或影响嗜酸性粒细胞介质水平的临床解释的信息。遗憾的是，很少有测试被验证可以定义比简单监测总血嗜酸性粒细胞计数更有用的独特临床或预后表型。在本文中，我们回顾了表型（细胞表面）标志物以及在疾病活动背景下检查的血清和组织标志物。我们还报告了一种用于检测可溶性 Siglec-8（sSiglec-8）的新型测定法的开发，sSiglec-8 是一种可能主要来源于嗜酸性粒细胞的蛋白质，作为一种潜在的血清生物标志物。该测定法包括使用重组 Siglec-8-Fc 融合蛋白的竞争性 ELISA。这项初步研究的目的是确定 sSiglec-8 是否是一种有用的生物标志物，可区分各种与嗜酸性粒细胞相关的疾病患者。总而言之，在推荐将包括 sSiglec-8 在内的各种生物标志物用于临床实践之前，迫切需要进行进一步的研究，以充分了解和验证其效用。
